Haddad, R. I., Ferrarotto, R., Guo, Y., Harrington, K. J., Licitra, L. F. L., Saba, N. F., Tahara, M., Nenclares, P., Braña, I., Xie, J., Chu, P., Ennis, M., Dobbs, J., Diorio, B., Kim, P., Shah, S., Burtness, B. (2026). OrigAMI-5: A randomized, phase 3 study of amivantamab plus pembrolizumab and carboplatin vs standard of care pembrolizumab plus platinum and 5-fluorouracil as first-line treatment in recurrent/metastatic head and neck cancer.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.tps6127